Patient-reported outcomes from a phase 2 PLATINUM trial of nivolumab combination therapy sparing concurrent cisplatin in nasopharyngeal carcinoma
Year: 2026
Type: article
Abstract: BACKGROUND: In the PLATINUM (ClinicalTrials.gov: NCT03984357) trial, nivolumab plus chemoradiotherapy sparing concurrent cisplatin demonstrated efficacy and safety in nasopharyngeal carcinoma (NPC). Herein, patient-reported outcomes (PROs) on quality of life (QoL), tolerability, and social reintegration are reported. METHODS: Patients with T4N1M0/T1-4N2-3M0 NPC were assessed for general and head-and-neck-specific QoL (using the European Organization for Research and Treatment of Cancer and the Functional Assessment of Cancer Therapy) and tolerability (using the PRO-specific Common Terminology Criteria for Adverse Events). Analyses included change over time, effect of the treatment phase on QoL, time-to-event analysis, and a comparison of PROs and clinician-reported outcomes (CROs) in toxicity. FINDINGS: Among 152 patients, 44.1% achieved social reintegration, and 51.3% were satisfied with their current life. Radiotherapy dominated QoL deterioration rather than induction chemotherapy (pooled mean difference, -18.51; 95% confidence interval [CI], -29.50 to -7.52; p = 0.001), and its removal dominated QoL improvement rather than that of nivolumab (pooled mean difference, -7.62; 95% CI, -10.05 to -5.19; p < 0.001). Patients without social reintegration had greater deterioration in speech (hazard ratio [HR], 0.60; 95% CI, 0.38 to 0.94; p = 0.027) and swallowing functions (HR, 0.59; 95% CI, 0.39 to 0.89; p = 0.011). Under-reporting of decreased appetite severity by CROs vs. by PROs in all three treatment phases was associated with poorer social reintegration (p = 0.002) and reduced failure-free survival (3 years, 86.1% vs. 95.0%; p = 0.021). CONCLUSIONS: Social reintegration is a practical composite indicator of favorable PROs in NPC. Interventions targeting speech, swallowing, and decreased appetite might promote better recovery. FUNDING: This study was funded by the Academician Workstation of Jun Ma (YSGZZ2024001), the Specific Research Fund of the Innovation Platform for Academicians of Hainan Province (YSPTZX202501), the National Natural Science Foundation of China (82573549, 82172870), the Guangdong Special Support Program for Young Top Talents (TZ09B0046), and the Guangzhou Science and Technology Program (2023A04J1786).
Source: Med
Authors: Cheng Xu, Ze-Qi Lin, Yu-Zhe Wang, Jia-Xi Shen, Wen-Fei Li, Guan-Qun Zhou, Kai-Bin Yang, Min-Yu Wen, Ying-Ni Zhang, Liang-Fang Shen, Kun-Yu Yang, Xiao-Zhong Chen, De-Sheng Hu, Shao-Jun Lin, Feng Jin, Ji-Bin Li, Ai-Hua Lin, Hong-Yun Zhao, Shu-Bin Hong, Hui-Ling Huang, Yuan Zhang, Xu Liu, Ying-Qin Li, Ling-Long Tang, Ying Sun, Jun Ma
Institutions: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University, Wuhan Union Hospital, Huazhong University of Science and Technology, Central South University, Xiangya Hospital Central South University, Zhejiang Cancer Hospital, University of Chinese Academy of Sciences, Hubei Cancer Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, Guiyang Medical University, Affiliated Hospital of Guizhou Medical University, The First Affiliated Hospital, Sun Yat-sen University, Chinese Society of Clinical Oncology, Hainan Medical University
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $9,350
Funders: National Natural Science Foundation of China, Hainan Provincial Department of Science and Technology, Siemens Healthineers, Tip-top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program, Guangzhou Science and Technology Program key projects, Guangzhou Municipal Science and Technology Project, Sun Yat-sen University Cancer Center
OpenAlex ID: W7128791727
